Loading...

LIMN LIMINATUS PHARMA INC US FDA Inspections 8-K Filing

LMNT

LMN

LIMINATUS PHARMA INC

(LIMN)

2025 8-K

Bylaw Amendment

Stock Offering Details

Settlement Agreement

Delisting Notice

Nasdaq Non-Compliance

Nasdaq Non-Compliance

Research Update

Investor Meetings

Non-Compliance Notification

Merger of Equals

Merger of Equals

External Links:

On August 14, 2025, Liminatus Pharma, Inc. provided an update on their immuno-oncology therapy IBA101. This filing is neutral and significant for the company.

AI Assistant

LIMINATUS PHARMA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.